Clinical analysis of 94 cases of ocular adnexal lymphomas

Abstract

To investigate the imaging manifestations and pathological features of ocular adnexal lymphoma (OALs) in order to provide relevant information for ophthalmologists. A total of 94 patients with OALs were pathologically confirmed between August 2018 and July 2023, and their demographics, location, subtype, treatment, and prognosis were retrospectively studied. 94 patients with OALs were included in this study, of whom 28 were female (29.79%) and 66 were male (70.21%). The age of the patients ranged from 21 to 80 years, with a predominance of 50–60 years (60/94); monocular onset was common (90/94), and the most site of onset was orbital (74/94), followed by conjunctiva (12/94), eyelids (4/94), vitreous (3/94), and lacrimal gland (1/94). CT and MRI can show the involvement and extent of the lesions, and the pathology of the disease is characterized by mucosa-associated lymphoid tissue marginal zone B-cell lymphoma (72/94), diffuse large B-cell lymphoma (10/94), T-cell lymphoma (4/94), mantle cell lymphoma (2/94), Burkitt's lymphoma (2/94), small lymphocytic lymphoma (2/94), and follicular lymphoma (1/94). All patients received surgical treatment, 42 patients received local radiation therapy, 35 patients received chemotherapy, 13 patients received radiation therapy and chemotherapy successively, and 3 patients received comprehensive treatment. During the follow-up, three patients relapsed, four died, one was lost to follow-up, and the remaining patients had stable conditions. The majority of OALs are mucosa-associated lymphoid tissue marginal zone B-cell lymphomas (MALT) with an excellent prognosis. It mostly occurs in people over 50 years of age and most site of the onset is orbital.

Keywords

clinical / ocular adnexal lymphoma / pathology

References

[1] Sassone M, Ponzoni M, Ferreri AJ. Ocular adnexal marginal zone lymphoma: clinical presentation, pathogenesis, diagnosis, prognosis and treatment. Best Pract Res Clin Haematol. 2017;30(1–2):118-130.

[2] Demirci H, Shields CL, Karatza EC, Shields JA. Orbital lymphoproliferative tumors: analysis of clinical features and systemic involvement in 160 cases. Ophthalmology. 2008;115(9):1626-1631.

[3] Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery lecture, part 1. Ophthalmology. 2004;111(5):997-1008.

[4] Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LLL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108(5):1451-1460.

[5] Koopman JH, van der Heiden Van Der Loo M, van Dijk MR, et al. Incidence of primary malignant orbital tumours in The Netherlands. Eye (Lond). 2011;25(4):461-465.

[6] Sjö LD, Ralfkiaer E, Prause JU, et al. Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005. Invest Ophthalmol Vis Sci. 2008;49(8):3283-3288.

[7] Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci. 2006;331(2):79-83.

[8] Svendsen FH, Heegaard S. Lymphoma of the eyelid. Surv Ophthalmol. 2017;62(3):312-331.

[9] Özkan MC, Palamar M, Tombuloğlu M, et al. Ocular adnexal lymphomas: single-center experience. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S158-S160.

[10] Desai A, Joag MG, Lekakis L, et al. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood. 2017;129(3):324-332.

[11] Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol. 2019;64(1):45-66.

[12] Oh SY, Kim WS, Kang HJ, et al. Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. Ann Hematol. 2018;97(10):1851-1857.

[13] Kalogeropoulos D, Papoudou-Bai A, Kanavaros P, Kalogeropoulos C. Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue. Clin Exp Med. 2018;18(2):151-163.

[14] Ponzoni M, Govi S, Licata G, et al. A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma. Oncologist. 2013;18(7):876-884.

[15] Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Gräff A, Buchen R, Witschel H. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American lymphoma. Br J Ophthalmol. 2001;85(1):63-69.

[16] Demirci H, Kauh CY, Rajaii F, Elner VM. Intralesional rituximab for the treatment of recurrent ocular adnexal lymphoma. Ophthalmic. Plast Reconstr Surg. 2017;33(3S Suppl 1):S70-S71.

[17] Alkatan HM, Alaraj A, El-Khani A, Al-Sheikh O. Ocular adnexal lymphoproliferative disorders in an ophthalmic referral center in Saudi Arabia. Saudi J Ophthalmol. 2013;27(3):227-230.

[18] Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol. 2004;242(2):130-145.

[19] Oh DE, Kim YD. Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol. 2007;125(12):1668-1673.

[20] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.

[21] Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.

[22] Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338(8776):1175-1176.

[23] Karlin J, Peck T, Prenshaw K, Portell CA, Kirzhner M. Orbital mantle cell lymphoma presenting as myasthenia gravis. Orbit. 2017;36(6):365-369.

[24] Daibata M, Komatsu T, Taguchi H. Human herpesviruses in primary ocular lymphoma. Leuk Lymphoma. 2000;37(3–4):361-365.

[25] Darwich R, Ghazawi FM, Rahme E, et al. Epidemiology of ophthalmic lymphoma in Canada during 1992-2010. Br J Ophthalmol. 2020;104(8):1176-1180.

[26] Sniegowski MC, Roberts D, Bakhoum M, et al. Ocular adnexal lymphoma: validation of American joint committee on cancer seventh edition staging guidelines. Br J Ophthalmol. 2014;98(9):1255-1260.

[27] Kiziltas B, Baskan C, Duman R, Dal MS. Ocular adnexal lymphomas: an eye care service experience in Turkey. Niger J Clin Pract. 2018;21(6):711-715.

[28] Nam SW, Woo KI, Kim YD. Characteristics of primary extranodal marginal zone B-cell lymphoma in Korea: conjunctiva versus other ocular adnexa. Br J Ophthalmol. 2018;102(4):502-508.

[29] Schiby G, Polak-Charcon S, Mardoukh C, et al. Orbital marginal zone lymphomas: an immunohistochemical, polymerase chain reaction, and fluorescence in situ hybridization study. Hum Pathol. 2007;38(3):435-442.

[30] Yu H, Du YX, Sun ZC, et al. Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China. Int J Ophthalmol. 2019;12(11):1731-1736.

[31] Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000;84(8):907-913.

[32] Lemke AJ, Kazi I, Felix R. Magnetic resonance imaging of orbital tumors. Eur Radiol. 2006;16(10):2207-2219.

[33] Coelho Siqueira SA, Ferreira Alves VA, Beitler B, Otta MM, Nascimento Saldiva PH. Contribution of immunohistochemistry to small B-cell lymphoma classificati. Appl Immunohistochem Mol Morphol. 2006;14(1):1-6.

[34] Mddile S, Coupland SE, Taktak A, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol. 2015;4:10.

[35] Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma. Ann Oncol. 2010;21(1):133-139.

[36] Agbay RL, Loghavi S, Medeiros LJ, et al. High-grade transformation of low-grade B-cell lymphoma: pathology and molecular pathogenesis. Am J Surg Pathol. 2016;40(1):e1-e16.

[37] Lin H, Wang H, Chen H. Diagnosis progression of mucosa-associated lymphoid tissue lymphoma. J Clin Exp Pathol. 2017;33(9):1010-1013.

[38] Ferreri AJ, Dolcetti R, Du MQ, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol. 2008;19(5):835-846.

[39] Masuda Y, Takeuchi K, Kodama T, et al. Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis. Int J Clin Oncol. 2019;24(12):1620-1628.

[40] Kim SY, Yang SW, Lee WS, et al. Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. Oncotarget. 2017;8(40):68583-68590.

[41] Ma WL, Yao M, Liao SL, et al. Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. Oncotarget. 2017;8(46):81329-81342.

[42] Munch-Petersen HD, Rasmussen PK, Coupland SE, et al. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study. JAMA Ophthalmol. 2015;133(2):165-173.

[43] Hindsø TG, Esmaeli B, Holm F, et al. International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma. Br J Ophthalmol. 2020;104(3):357-362.

[44] Rasmussen P, Sjö LD, Prause JU, Ralfkiaer E, Heegaard S. Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol. 2009;93(8):1047-1051.

[45] Woog JJ, Kim YD, Yeatts RP, et al. Natural killer/T-cell lymphoma with ocular and adnexal involvement. Ophthalmology. 2006;113(1):140-147.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.